FLG rs61816766: Understanding the R501X Variant
The rs61816766 variant, commonly known as R501X, is a loss-of-function mutation in the FLG gene that disrupts the production of the filaggrin protein. This genetic change is significantly associated with an increased risk of developing atopic dermatitis and other skin barrier-related conditions.
What each genotype means
Typical filaggrin function
This genotype represents the common, functional version of the FLG gene. Individuals with this profile do not carry the R501X loss-of-function mutation, which is associated with reduced filaggrin protein production and impaired skin barrier function.
This is the most common genotype, found in the vast majority of the global population.
Increased risk of barrier impairment
Carrying one copy of the T allele (also known as R501X) is associated with a higher statistical likelihood of developing atopic dermatitis and related skin barrier issues. This variant leads to a loss of filaggrin protein, which may result in increased transepidermal water loss and a higher susceptibility to allergic sensitization.
This genotype is carried by approximately 1 in 30 to 1 in 50 people of European ancestry, though it is less common in other populations.
High risk of barrier impairment
Carrying two copies of the T allele (R501X) significantly reduces the production of functional filaggrin protein in the skin. This genotype is strongly associated with ichthyosis vulgaris and a higher risk for moderate-to-severe atopic dermatitis, food allergies, and other allergic conditions. Individuals with this profile should focus on maintaining skin hydration and may wish to discuss skin barrier management with a dermatologist.
This genotype is rare, occurring in a small fraction of the population, primarily within European descent groups.
What is the rs61816766 Variant?
The rs61816766 variant, frequently referred to in scientific literature as R501X, is a specific change in the DNA sequence of the FLG gene. This variant is classified as a nonsense mutation, meaning it introduces a premature stop signal during the process of protein synthesis. Because of this stop signal, the cell stops building the protein before it is complete, resulting in a truncated and non-functional version of the filaggrin protein. This variant is located within the epidermal differentiation complex on chromosome 1. Because it prevents the production of full-length filaggrin, it is categorized as a loss-of-function mutation. This means that individuals carrying this variant have a reduced capacity to produce the essential protein required for maintaining the integrity of the outermost layer of the skin, known as the stratum corneum.
The Role of the FLG Gene
The FLG gene provides instructions for making a protein called filaggrin, which is essential for the health and function of the skin. Filaggrin acts as a structural protein that helps bundle keratin filaments together, which is crucial for the formation of a strong, protective skin barrier. As skin cells mature and move toward the surface, filaggrin is broken down into smaller components, including amino acids that serve as natural moisturizing factors. These factors are vital for retaining water and maintaining the skin's pH balance. When the FLG gene is mutated, as is the case with rs61816766, the skin barrier becomes compromised. This structural weakness allows moisture to escape more easily and makes the skin more susceptible to irritation, allergens, and environmental pathogens, which can trigger inflammatory responses.
Research and Clinical Associations
Research has consistently identified FLG loss-of-function variants, including rs61816766, as significant predisposing factors for atopic dermatitis, commonly known as eczema. Studies have shown that individuals with these mutations are more likely to experience persistent skin symptoms and may have a higher risk of developing the 'atopic march,' a progression from eczema to other allergic conditions like asthma and hay fever. The evidence for this association is considered strong in clinical genetics, particularly within European populations. However, it is important to note that having this variant does not guarantee the development of these conditions. Many people with the variant do not develop severe symptoms, and many people with atopic dermatitis do not carry this specific mutation. The condition is complex, involving a combination of genetic, environmental, and lifestyle factors that interact to influence overall skin health.
Population Frequency
The prevalence of the rs61816766 variant varies significantly across different ancestral groups. It is most commonly observed in populations of European descent, where the minor allele frequency is typically estimated between 0.02 and 0.04. In some studies, the frequency of carrying at least one null allele in European cohorts has been reported to be higher. Conversely, this variant is much less common in individuals of African or Asian ancestry. Because the distribution of this genetic change is highly dependent on ancestry, its impact on skin health is not uniform globally. Researchers continue to study these frequency differences to better understand how genetic background influences the risk of skin barrier disorders across diverse human populations.
Interpreting Your Genetic Information
Understanding your genetic status regarding rs61816766 can provide insight into your biological predisposition for skin barrier function, but it should not be used for medical diagnosis. Genetic testing results are only one piece of a much larger puzzle. If you are concerned about skin conditions like atopic dermatitis, it is essential to consult with a dermatologist or a primary care physician. They can evaluate your symptoms, medical history, and environmental factors to provide an accurate assessment and discuss appropriate management strategies. There is no 'treatment' for the genetic variant itself, but many people manage skin barrier issues effectively through consistent use of emollients, moisturizers, and other dermatological care recommended by professionals. Always discuss any concerns about your skin health with a qualified healthcare provider rather than relying solely on genetic data.
How common is this variant?
The rs61816766 variant is most prevalent in European populations with a minor allele frequency of approximately 0.02 to 0.04, while it is significantly less common in other ancestral groups.
Frequently asked questions
Does having the R501X mutation mean I will get eczema?
No, having this mutation does not guarantee that you will develop eczema. While it is a known risk factor, many other genetic and environmental factors contribute to the development of skin conditions.
Can I fix my FLG gene if I have this variant?
Currently, there is no medical treatment to 'fix' or change a genetic variant. Management focuses on supporting the skin barrier through proper hydration and dermatological care.
Is rs61816766 the same as R501X?
Yes, rs61816766 is the unique identifier (rsID) used in scientific databases to refer to the specific genetic change known as R501X in the FLG gene.
Should I get tested for this variant?
Genetic testing for this variant is generally not required for clinical diagnosis of skin conditions. If you have concerns about your skin, it is best to speak with a dermatologist.
Sources & further reading
Educational information only, last refreshed 9/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs61816766?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in FLG
A well-characterized loss-of-function null mutation (2282del4) in filaggrin predisposing individuals to cutaneous allergen penetration and the atopic march.
Loss-of-function variant (p.Lys501Ter) in FLG, a major predisposing factor for atopic dermatitis and ichthyosis vulgaris.
Filaggrin missense and splice-region variant associated with skin barrier disruption, atopic dermatitis, and allergic sensitization.
Loss-of-function mutation 2282del4 in filaggrin predisposing to peanut allergy.
Filaggrin coding variant associated with skin barrier disruption and allergic conditions.
A filaggrin locus variant associated with impaired epidermal barrier function, predisposing to atopic dermatitis and allergic sensitization.